Adverse skin reactions to nicotine in a transdermal therapeutic system.
Nicotine in a transdermal therapeutic system (TTS) has been introduced recently to help people to stop smoking. 14 volunteers (10 male, 4 female) with a history of former adverse skin reactions to this device were investigated. Skin tests for contact urticaria and patch tests for contact allergy were done with the individual components of the TTS. Contact sensitization to nicotine was identified in 5 and to the TTS itself in 1 individual. Irritant reactions due to occlusion were present in 9 subjects. The optimal test agent and concentration for elucidating the adverse skin reaction was an aqueous solution of 10% nicotine base. Atopy, as diagnosed by history and skin prick tests to common inhalant allergens, and contact sensitization to standard patch test allergens, were each identified in 6 subjects. Nicotine should be added to the expanding list of transdermally delivered drugs which may elicit contact dermatitis.
Bircher
A J
AJ
Department of Dermatology, University of Basel, Switzerland.
Howald
H
H
Rufli
T
T
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D003877:Dermatitis, Contact / Q000209:etiology*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000009:adverse effects*; D010328:Patch Tests; D000074606:Smoking Prevention
D009538:Nicotine